Marcus Vinicius Della Coletta

Marcus Vinicius Della Coletta

Auto-generated profile, based on publicly available information

Marcus Vinicius Della Coletta

Universidade Estadual do Amazonas, Escola de Ciências da Saúde Manaus AM, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
RSRoberta Arb Saba
Roberta Arb Saba
DMDébora Palma Maia
Débora Palma Maia
FCFrancisco Eduardo Costa Cardoso
Francisco Eduardo Costa Cardoso
VBVanderci Borges
Vanderci Borges
LALuiz Augusto F. Andrade
Luiz Augusto F. Andrade
MCMarcus Vinicius Della Colletta
Marcus Vinicius Della Colletta
The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best evidence to the Brazilian reality. Thus, the main published treatment guidelines were reviewed based on the recommendations of group from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology.

1 June 2015 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
MPMárcia M.G. Pimentel
Márcia M.G. Pimentel
FRFabíola C. Rodrigues
Fabíola C. Rodrigues
MLMarco Antônio A. Leite
Marco Antônio A. Leite
MJMário Campos Junior
Mário Campos Junior
ARAna Lucia Rosso
Ana Lucia Rosso
CRCíntia Rebouças
Cíntia Rebouças

28 November 2022 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
PCPaulo Caramelli
Paulo Caramelli
VMValeska Marinho
Valeska Marinho
JLJerson Laks
Jerson Laks
MCMarcus Vinicius Della Coletta
Marcus Vinicius Della Coletta
FSFlorindo Stella
Florindo Stella
PBPaulo Henrique Ferreira Bertolucci
Paulo Henrique Ferreira Bertolucci
RESUMO Atualmente não há tratamento curativo para as demências neurodegenerativas ou para a demência vascular, mas algumas intervenções farmacológicas e não farmacológicas podem contribuir para aliviar os sintomas, retardar a progressão da doença e melhorar a qualidade de vida. As abordagens terapêuticas atuais são baseadas na etiologia, no perfil dos sintomas e no estágio da demência. Neste artigo apresentamos recomendações sobre os tratamentos farmacológicos e não farmacológicos da demência devida à doença de Alzheimer, comprometimento cognitivo vascular, demência frontotemporal, demência da doença de Parkinson e demência com corpos de Lewy.

1 July 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
CGClecio Godeiro
Clecio Godeiro
Carina FrançaCarina França
Carina França
RCRafael Bernhart Carra
Rafael Bernhart Carra
FSFelipe Saba
Felipe Saba
RSRoberta Saba
Roberta Saba
RCRubens Gisbert Cury
Rubens Gisbert Cury
Background: Noninvasive stimulation has been widely used in the past 30 years to study and treat a large number of neurological diseases, including movement disorders. Objective: In this critical review, we illustrate the rationale for use of these techniques in movement disorders and summarize the best medical evidence based on the main clinical trials performed to date. Methods: A nationally representative group of experts performed a comprehensive review of the literature in order to analyze the key clinical decision-making factors driving transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) in movement disorders. Classes of evidence and recommendations were described for each disease. Results: Despite unavoidable heterogeneities and low effect size, TMS is likely to be effective for treating motor symptoms and depression in Parkinson’s disease (PD). The efficacy in other movement disorders is unclear. TMS is possibly effective for focal hand dystonia, essential tremor and cerebellar ataxia. Additionally, it is likely to be ineffective in reducing tics in Tourette syndrome. Lastly, tDCS is likely to be effective in improving gait in PD. Conclusions: There is encouraging evidence for the use of noninvasive stimulation on a subset of symptoms in selected movement disorders, although the means to optimize protocols for improving positive outcomes in routine clinical practice remain undetermined. Similarly, the best stimulation paradigms and responder profile need to be investigated in large clinical trials with established therapeutic and assessment paradigms that could also allow genuine long-term benefits to be determined.

1 April 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
SBSonia Maria Dozzi Brucki
Sonia Maria Dozzi Brucki
TATarso Adoni
Tarso Adoni
CACarlos Mauricio O MAURICIO OLIVEIRA de Almeida
Carlos Mauricio O MAURICIO OLIVEIRA de Almeida
DADaniel Ciampi de Andrade
Daniel Ciampi de Andrade
RARenato Anghinah
Renato Anghinah
GPGilmar Fernandes do Prado
Gilmar Fernandes do Prado
Cannabinoids comprehend endocannabinoids, phytocannabinoids, and synthetic cannabinoids, with actions both in the central and peripherical nervous systems. A considerable amount of publications have been made in recent years, although cannabis has been known for over a thousand years. Scientific Departments from the Brazilian Academy of Neurology described evidence for medical use in their areas. Literature is constantly changing, and possible new evidence can emerge in the next days or months. Prescription of these substances must be discussed with patients and their families, with knowledge about adverse events and their efficacy.

19 March 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
VTVitor Tumas
Vitor Tumas
MAMarcelo Jhonatan Aureliano
Marcelo Jhonatan Aureliano
CRCarlos R. M. Rieder
Carlos R. M. Rieder
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
HFHenrique B. Ferraz
Henrique B. Ferraz
IMIgnacio Fernandez Mata
Ignacio Fernandez Mata
The etiology of Parkinson's disease (PD) is complex and multifactorial, depending on interactions involving environmental/lifestyle and genetic factors. The genetic aspects of the disease are becoming well characterized, while the environmental factors still need further investigation. In the present narrative review, we have described the most concrete evidence of associations between environmental factors and the risk of developing PD. Physical activity, healthy dietary patterns, smoking, and caffeine intake are protective factors against PD. Head trauma, consumption of milk and dairy products, and pesticide exposure were associated with a higher risk of developing PD. The associations of alcohol consumption, living in rural areas, farming, and consumption of well water with PD are still controversial. Results of several studies strongly suggest that diabetes mellitus is a risk factor for the development of PD, as well as the pre-diabetic state. Lower serum levels of uric acid were associated with an increased risk of developing PD and with worse clinical features and faster progression of symptoms. The protective effects of nonsteroidal antiinflammatory drugs use are controversial. Several other factors were potentially associated with the risk of developing PD: environmental pollutants such as organic solvents, exposure to sunlight, vitamin D deficiency, bullous pemphigoid, bipolar disorder, inflammatory bowel disease, irritable bowel syndrome, certain infections and agents, and essential tremor. Environmental factors are important risk markers for the development of PD. Understanding these risks and protective factors could lead to the implementation of risk-modifying actions for PD.